Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. by Tholouli, E, Watt, S, Lucas, G, Burthem, J, Yin, J, Cavet, J, Greenfield, H, Houghton, J

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy by Loke, J, Metzner, M, Boucher, R, Jackson, A, Hopkins, L, Pavlu, J, Tholouli, E, Drummond, M, Peniket, A, Bishop, R, Fox, S, Vyas, P, Craddock, C

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. by Craddock, C, Nagra, S, Peniket, A, Brookes, C, Buckley, L, Nikolousis, E, Duncan, N, Tauro, S, Yin, J, Liakopoulou, E, Kottaridis, P, Snowden, J, Milligan, D, Cook, G, Tholouli, E, Littlewood, T, Peggs, K, Vyas, P, Clark, F, Cook, M, Mackinnon, S, Russell, N

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia by Craddock, C, Jackson, A, Loke, J, Siddique, S, Hodgkinson, A, Mason, J, Andrew, G, Nagra, S, Malladi, R, Peniket, A, Gilleece, M, Salim, R, Tholouli, E, Potter, V, Crawley, C, Wheatley, K, Protheroe, R, Vyas, P, Hunter, A, Parker, A, Wilson, K, Pavlu, J, Byrne, J, Dillon, R, Khan, N, McCarthy, N, Freeman, SD